Background Epidermolysis bullosa (EB) is a group of rare and currently incurable genetic blistering disorders. As more pathogenic-driven therapies are being developed, there is an important need for EB-specific validated outcomes measures designed for use in clinical trials. Objectives To test the reliability and construct validity of an instrument for scoring clinical outcomes of research for EB (iscorEB), a new combined clinician-and patient-reported outcomes tool. Methods We conducted an observational study consisting of independent 1-day assessments (six assessors) at two academic hospitals. The assessments consisted of iscorEB clinician (iscorEB-c), Birmingham Epidermolysis Bullosa Severity (BEBS) and global severity assessment for physicians; and iscorEB patient (iscorEB-p), Quality of Life evaluation in Epidermolysis Bullosa and Children's Dermatology Life Quality Index for patients. Construct validity and intraclass correlation coefficients (ICCs) for interobserver, intraobserver and test-retest reliability were calculated. Results Overall, 31 patients with a mean age of 19Á5 years (1Á8-45Á2) were included. Disease severity was mild in 42% of cases, moderate in 29% and severe in 29%. The interobserver ICC was 0Á96 for both the clinician-reported section of iscorEB-c and BEBS. The ICC for intraobserver reliability was 0Á91 and 0Á70 for the skin and mucosal domains of iscorEB-c, respectively. Cronbach's alpha for iscorEB-c was 0Á89. The test-retest reliability of iscorEB-p was 0Á97 and Cronbach's alpha was 0Á84. The clinical score differentiated between subjects with mild, moderate and severe disease, and both clinical and patient subscores discriminated between recessive dystrophic EB and other EB subtypes. Conclusions iscorEB has robust reliability and construct validity, including strong ability to distinguish EB types and severities. Further studies are planned to test its responsiveness to change.
• The iscorEB has robust reliability and construct validity, including a strong ability to distinguish EB types and severities.
The inherited forms of epidermolysis bullosa (EB) are a group of rare, devastating and currently incurable genetic blistering disorders characterized by fragility of skin and mucosa. The estimated incidence and prevalence of EB in the U.S.A. are 19 per million live births and 8 per million, respectively. 1 The most recent classification system for EB includes four major types (simplex, junctional, dystrophic and Kindler syndrome) determined by the location of cleavage in relation to the dermoepidermal basement membrane zone and further refined by phenotype, inheritance pattern, the affected protein and genetics. 2 The severity of EB depends on the subtype and ranges from limited skin involvement to a devastating, multisystem disorder with secondary complications in many organ systems and reduced life expectancy. There is no cure or well-accepted disease-modifying treatment for EB at this time. Treatment is palliative with the aims of promoting patient well-being, optimizing wound healing 3 and monitoring for, and treatment of, secondary complications. 4 New therapies targeting the pathogenesis of EB are currently being studied in preclinical or early phase trials; [5] [6] [7] [8] [9] [10] therefore, validated and accepted measures of meaningful improvement from clinical and patient perspectives are needed. We currently lack a robust and reliable EB-specific outcome measurement tool that could be used in clinical research. Existing instruments have significant limitations, such as design flaws and insufficient validation, which restrict their widespread use in clinical trials. The Birmingham Epidermolysis Bullosa Severity score (BEBS) was created to assess EB severity and emphasizes many of the chronic and irreversible changes that occur in EB, such as scarring. 11 BEBS is potentially less sensitive to capturing improvement resulting from a therapeutic intervention, and its responsiveness has not been tested. The recently published Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) separates disease activity from scarring, but its responsiveness has not been tested either. 12 In addition, both BEBS and EBDASI do not capture complications in nonskin or nonmucosal organ systems, nor do they capture patient-reported perceptions of severity. Quality of Life evaluation in Epidermolysis Bullosa (QOLEB) is an EB-specific, patient-reported quality-of-life instrument, but it has not been widely studied in children, who are disproportionally affected by severe forms of EB. 13 Generic dermatological quality-of-life measures such as the Dermatology Life Quality Index (DLQI) 14 and Children's Dermatology Life Quality Index (CDLQI) 15, 16 do not capture dimensions specific to EB, making them less sensitive for this patient population. The DLQI and the CDLQI were used in a descriptive study of Scottish patients with EB, 17 but have not been used in clinical trials of therapies for EB.
The absence of a widely accepted, comprehensive, EB-specific outcome instrument is a significant unmet need in EB clinical research. The instrument for scoring clinical outcomes of research for EB (iscorEB) was developed with this gap in mind, using a rigorous methodology and international collaboration involving EB clinical experts and patients with EB that derived and refined the content of iscorEB with an emphasis on items that may change over time, particularly as a result of intervention. 18 Therefore, iscorEB is unique in that it evaluates the cutaneous and mucosal impact of EB in addition to its impact on other organs, and includes clinician-and patientreported outcomes in a single instrument (File S1; see Supporting Information). Our central hypothesis for this study is that iscorEB is a reliable and valid outcome instrument that measures clinically relevant and patient-important outcomes specific to EB. Thus, the objective of this study was to evaluate the reliability and construct validity of iscorEB among care providers and patients with EB.
Patients and methods
We conducted this study at two academic, tertiary institutions with specialized EB clinics, namely Children's Hospital Colorado (affiliated with the University of Colorado School of Medicine) in Aurora, CO, U.S.A. and The Hospital for Sick Children in Toronto, Ontario, Canada (affiliated with the University of Toronto). The institutional review boards at each site reviewed and approved the study.
Study population
We recruited a convenience sample of participants from the EB clinics at each hospital and through referrals from two EB advocacy groups, namely The Dystrophic Epidermolysis Bullosa Research Association (www.debra.org) and the Jackson Gabriel Silver Foundation, now called Epidermolysis Bullosa Research Partnership (www.ebrp.org). Eligible subjects had a physician-verified diagnosis of EB simplex, junctional EB or dystrophic EB based on clinical findings, biopsy and/or genetic testing, were between 1 and 50 years old and were physically capable of travelling to and from the study site and participating in the study activities. Subjects and families unable to read and understand English with at least moderate fluency were excluded. We recruited an equal number of paediatric (1-17 years of age) and adult (≥ 18 years of age) subjects. In addition, we planned to distribute enrolment across three levels of severity determined by the principal investigator at each site using the following definitions: 'mild' was defined as localized skin involvement (typically less than 5% body surface area) and no associated systemic complications, 'moderate' was defined as widespread skin involvement and two or fewer nonskin manifestations or complications and 'severe' was defined as generalized skin involvement and three or more nonskin manifestations or complications. Written informed consent was obtained from all subjects or their parents/guardians.
Study instrument
The clinician-reported section of iscorEB (iscorEB-c) has five domains, i.e. skin involvement, mucosal involvement, internal organ involvement, laboratory abnormalities and complications/procedures, totalling 114 points (File S1; see Supporting Information). Items are completed based on a comprehensive examination of the skin and mucosa and a review of the medical history. The patient-reported section (iscorEB-p) contains 15 straightforward questions and covers seven domains, i.e. pain, itch, essential functions, sleep, daily activities, mood and impact. Each question is scored using a range of 0-8 points, with a maximum of 120 points.
Study procedures

Physician assessments
Six physicians with a range of perspectives in the care of EB participated in this study; A.L.B., I.L.-C., A.W.L. and E.P. are paediatric dermatologists, J.A.F. is a paediatrician specializing in children with special medical needs and J.T. is a paediatric bone marrow transplant physician who uses this procedure to treat EB. Four of the six physicians participated in each evaluation day. Training meetings to review the format of the sessions and the use of the outcomes instruments were held prior to each evaluation. Before the first clinical assessment, each subject was placed in a private room, removed his or her clothing and bandages, and standardized photographs were taken. The first assessment included a review of the subject's medical history and recent laboratory studies and interventions, in addition to a complete examination of the skin and mucosa. Following a break, the second assessment consisted of an examination of the skin and mucosa only. In the case of six subjects with recessive dystrophic EB (RDEB), photographs were used for the second skin assessment, as these subjects could not tolerate remaining unbandaged for an extended period.
Physicians examined subjects independently or in pairs, but were not allowed to discuss the examination findings or historical data. Each physician completed iscorEB-c and BEBS independently during their first assessment. In addition, each physician rated the subject's global disease severity (Physician's Global Assessment) as mild, moderate or severe based on his or her overall clinical impression. For the second assessment, subjects were evaluated in a different order than in the first round. Only the skin and mucosal domains of iscorEB-c, which rely on clinical judgement, were completed after the second assessment.
Patient-reported outcomes
Prior to the first clinical assessment, each subject completed iscorEB-p. In addition, subjects aged 18 years and older completed QOLEB, while subjects aged 4-17 years completed the CDLQI. Subjects aged 3-7 years were allowed assistance from an adult to complete the CDLQI. At the end of the day, subjects completed iscorEB-p again.
Statistical analysis
Based on feasibility, we initially proposed a sample size of 40 subjects and five physicians. Assuming an intraclass correlation coefficient (ICC) of 0Á7, this sample size allowed 95% confidence intervals of AE 0Á12 for interobserver reliability and AE 0Á16 or smaller for test-retest reliability. Our final sample size of 31 subjects and six physicians yielded 95% confidence intervals of AE 0Á15 for interobserver reliability and AE 0Á20 for test-retest reliability, which we considered to be acceptable levels of precision.
To assess interobserver, intraobserver and test-retest reliability, we used a repeated measures, random effects ANOVA model to calculate the ICC. The models contained an overall mean, random variation between subjects, and residual errors; the latter two were used to calculate the correlations. The domains and total scores of iscorEB-c were compared between physicians to determine interobserver reliability. Correlation was estimated as the ratio of the variance between subject scores to the total variance in the sample. The skin and mucosal domains of iscorEB-c from repeat clinical assessments by the same physician were used to determine intraobserver reliability. Repeated iscorEB-p assessments were used to calculate test-retest reliability.
To assess the internal consistency of iscorEB-c and iscorEBp, we calculated the Cronbach's alpha. To test the convergent validity of iscorEB, domains from iscorEB-c were compared with the BEBS, and iscorEB-p was compared with QOLEB or CDLQI using Spearman's correlation.
Finally, to test whether iscorEB scores could discriminate between different subtypes and severities of EB, we hypothesized that subjects with RDEB would have higher iscorEB scores than those with other EB subtypes and that subjects with more severe EB would have higher iscorEB scores. A repeated measures, mixed model using linear contrasts with corresponding F-statistics was used to compare iscorEB-c scores, domain subscores and iscorEB-p scores across groups defined by the median Physician's Global Assessment score and across subjects with RDEB vs. other disease subtypes.
All analyses were performed using SAS version 9Á3 (SAS Institute Inc., Cary, NC, U.S.A.).
Results
A total of 31 subjects participated in the study; 17 at the Hospital for Sick Children and 14 at the University of Colorado. Subject characteristics are shown in Table 1 . A.L.B., E.P. and J.T. each assessed all 31 subjects, while I.L.-C. and A.W.L. assessed 17 subjects and J.A.F. assessed 14 subjects. The mean time between the first and second set of physician assessments was 3Á2 AE 1Á0 h (range 2Á1-5Á1), and the mean time between completions of the patient questionnaires was 3Á4 AE 0Á5 h (range 2Á5-4).
The iscorEB scores, ICCs for interobserver, intraobserver and test-retest reliability and Cronbach's alpha for this sample are reported in Table 2 . The interobserver ICC was 0Á96 for both the clinician-reported section of iscorEB (iscorEB-c) and BEBS, showing comparable reliability between investigators on the two instruments. The ICC for intraobserver reliability was 0Á91 and 0Á70 for the skin and mucosal domains of iscorEB-c, respectively. Cronbach's alpha for the clinical portion of iscorEB was 0Á89, which again was comparable with BEBS. In addition, domain scores ranged from 0Á85 to 0Á88, suggesting that each clinical domain is relevant to the instrument. For the patient-reported section of iscorEB (iscorEB-p), the ICC for test-retest reliability was 0Á97, and Cronbach's alpha was acceptable at 0Á84, which was slightly lower than that for QOLEB, but higher than that for CDLQI.
The correlation of iscorEB with similar instruments is shown in Table 3 . Overall, iscorEB-c correlated well with BEBS. The internal organ, laboratory abnormalities and complications domains correlated less well than skin and mucosal involvement with the BEBS total score. The iscorEB-p had a strong correlation with QOLEB, while the correlation with CDLQI was reasonable but less robust. The overall correlation of iscorEB-c and iscorEB-p was reasonable (0Á67).
Overall, iscorEB-c demonstrated a good ability to discriminate between subjects in this cohort with mild, moderate and severe EB and between subjects with RDEB vs. other forms of EB (Fig. 1a) . Each clinical domain could distinguish between subjects with mild vs. severe disease and RDEB vs. other forms of EB, but differentiation for the mucosal, internal organ and complications/procedures domains was not statistically significant between subjects with moderate-to-severe severity for the mucosal domain or between mild-to-moderate severity for the internal organ and complications/procedures domains. Likewise, iscorEB-p could distinguish between subjects with mild vs. severe disease and RDEB vs. other forms of EB (Fig. 1b) , but differentiation between mild-to-moderate and moderateto-severe disease was not statistically significant. For subjects with RDEB, iscorEB-c correlated with age (r = 0Á51, P < 0Á001). Age did not correlate with iscorEB-c in subjects who did not have RDEB nor with iscorEB-p in either disease subgroup.
Discussion
Ideal outcome instruments for use in clinical trials of treatments for EB should be EB-specific, able to assess clinically relevant and patient-important signs and symptoms that are likely to change as a result of intervention, noninvasive, easy to use and complementary to biological markers (e.g. collagen VII expression in the case of RDEB).
In this study, we have demonstrated that iscorEB, which evaluates both clinical and patient-reported outcomes, is a reliable and valid outcomes instrument that satisfies many of these characteristics. The novelty of our tool is that it could be used as a composite score, combining the clinician-and patient-reported outcomes or as separate clinician and patient subscores. The combined score decreases the need for using different scoring systems in a clinical trial. Furthermore, we documented that patients with mild forms of EB have very low clinician scores (mean 2Á84, 2Á5% of iscorEB-c) but moderate-range patient scores (mean 23Á85, 20% of iscorEB-p), demonstrating that a clinician-only perspective tends to minimize the disease severity, especially in the milder spectrum of disease. The ultimate impact of a disease is derived from the patient's impression of the degree of illness; therefore, having the perspective of both the clinician and the patient is likely to create a more reliable picture of disease severity.
In terms of interobserver reliability, the clinical portion of iscorEB compared favourably with BEBS. Our team of assessors came from both dermatological and nondermatological backgrounds, showing that a range of physicians who care for a patient with EB can utilize these outcomes instruments to assess patients with EB. This derives from our prior work on the development of the score, which emphasized that items being part of the clinician portion should be specific, descriptive and easy to measure by a nonspecialist (e.g. not necessary to have an ophthalmologist score the eye changes). 18 In this study, only the skin and mucosal portions of iscorEB-c were repeated to test intraobserver reliability, as these are the only All values are n (%) unless otherwise stated.
two parts of the assessments that rely on clinical judgement. The ICCs for these domains were 0Á91 and 0Á70, respectively. While acceptable, the lower ICC for mucosal involvement suggests that this domain could be further refined. Our investigators remarked that measuring mouth opening was more difficult than expected, and the scale was more suited to an adult's mouth than a child's mouth.
Internal reliability (Cronbach's alpha) for iscorEB-c, its domains and iscorEB-p was high, showing that each section of the instrument contributes to the score (File S1; see Supporting Information). Within the mucosal, internal organ and laboratory domains of iscorEB-c, certain items performed less well, either as a result of low rates of endorsement or low rates of response, and will be re-evaluated further as we refine the instrument. For example, signs and symptoms of airway involvement were assessed in each subject, but it was extremely rare to have a score higher than zero, which was due to a lack of findings. However, the presence of these findings, Cronbach's alpha
BEBS, Birmingham Epidermolysis Bullosa Severity score; QOLEB, Quality of Life evaluation in Epidermolysis Bullosa; CDLQI, Children's Dermatology Life Quality Index; iscorEB, instrument for scoring clinical outcomes of research for epidermolysis bullosa. Comparison (n = 31 unless specified otherwise)
Spearman's rho (P-value) iscorEB-c vs. BEBS (total score) iscorEB-c total score Mean iscorEB-c (a) and iscorEB-p (b) score are shown for disease severity and recessive dystrophic epidermolysis bullosa (RDEB) vs. other disease subtypes. For disease severity overall, F 2,28 = 56Á3 (P < 0Á001) for iscorEB-c, and F 2,28 = 6Á51 (P = 0Á005) for iscorEB-p. Error bars represent SDs.
although uncommon, would be clinically significant and likely to contribute to disease severity. Thus, we plan to keep these items in the instrument. Similarly, the lower significance of the laboratory findings was likely related to the fact that many subjects did not have tests performed that could be scored. However, we feel these items are relevant to disease severity and plan to keep them in the instrument. In the context of a clinical trial these items are likely to be assessed consistently; therefore, it is important to keep them as part of the tool. We compared iscorEB-c with BEBS and found a good correlation of both the total score and domain scores with the BEBS total score, supporting the view that iscorEB-c assesses relevant disease manifestations. The iscorEB-p also compared favourably with QOLEB and reasonably well with the CDLQI. Except for internal organ involvement, iscorEB-c and iscorEB-p showed a reasonable correlation.
In our study population, iscorEB-c demonstrated a good ability to discriminate between patients with mild, moderate and severe EB. These results are similar to those found during pilot testing of iscorEB as previously reported. 18 In addition, iscorEB-c is able to distinguish between RDEB and other disease subtypes as a whole. We chose not to evaluate these disease subtypes separately in our analyses because of the small number of patients in each group. A similar trend was seen for the iscorEB-p, although the differences between mild-to-moderate and moderate-to-severe EB were not statistically significant. To our knowledge, a formal definition of clinically meaningful disease change for EB does not exist. Our data suggest that a change of 16 points in the iscorEB-c score (going from moderate to severe or vice versa) is likely to be clinically significant, as the calculated minimally important difference (0Á5 SD) is 5Á5 points. Additional studies are needed to establish a more precise estimate of the clinically significant difference and a better understanding of the scores, particularly in response to changes over time.
The iscorEB was designed with the intent to be used in clinical trials. Thus, it emphasizes clinical characteristics that will likely change because of intervention. The skin involvement domain assesses active blisters, erosions and associated crusts/scabs in addition to chronic wounds and infection. The score reflects the type of lesions, in addition to the percentage of involvement for an affected region; each region of the body is weighted as in the Psoriasis Area and Severity Index. 19 As a child's proportions are different from those of an adult, we plan to include a paediatric scale in the next version of iscorEB. The skin component of BEBS also evaluates the percentage of the body affected but includes 'healing skin, erythema and atrophic scarring' in the assessment. Scarring is unlikely to change, making this assessment less useful for clinical trials. The newly described Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) distinguishes disease activity (blisters and erosions) from chronic changes. Active lesions are assessed based on the number and size of lesions in a body region. We did not compare iscorEB with EBDASI as EBDASI had not been published when our study was planned. Both BEBS and EBDASI do not capture complications in nonskin or nonmucosal organ systems. Our prior work with item generation and expert consensus showed that including these areas was important. The internal organ, laboratory abnormalities and complications/procedures domains of iscorEB comprise about 30% of the total clinical score, and our Cronbach's alpha values support their contributions to the instrument. Both the CDLQI and Epidermolysis Bullosa Quality of Life (EBQOL) are measures of quality of life, while iscorEB-p was designed to assess patient perceptions of aspects of their disease that may change as a result of intervention. There are notable differences in the content of these instruments that reflect this intent. For instance, EBQOL includes one question about pain, whereas iscorEB-p assesses overall pain in addition to skin, mouth, eye and bone/joint pain. The iscorEB-p also assesses itch, which has been found to be a significant concern of patients with EB. 20 Unlike EBQOL, iscorEB-p does not emphasize independence, relationships, finances and emotional complexities (other than mood). We do not view these differences as a deficiency of iscorEB-p. Rather, they simply highlight our emphasis on assessing outcomes that may change as a result of intervention and outcomes that are perceived to be important by patients affected by EB. This study must be considered in the context of several limitations. The sample size was smaller than initially calculated; however, the P-values suggest that the data is reliable. Many of the subjects, particularly those with mild or moderate disease, did not have data for certain items owing to lack of severity or information, thus creating a floor effect. Some of these items (e.g. scoring of the mouth opening) were modified in the new version of the instrument (File S1; see Supporting Information). Other items, such as missing laboratory information, are less likely to be absent in the context of a trial, thus minimizing this limitation. Certain domains, particularly the internal organ domain and complications/procedures domain, need to be further assessed in a larger group of patients. Despite our efforts, participants with certain EB subtypes, such as Kindler syndrome and junctional EB, could not be recruited because of the rarity of their condition. However, we considered that the range of disease severity could allow for the generalization of our findings to other subtypes that are not included but may be easily classified into one of the severity categories. There was no ceiling effect observed; the mean cohort iscorEB was a small portion of the maximum values.
In conclusion, measuring the activity and severity of EB is a challenge owing to its rarity, clinical heterogeneity and the wide range of ages of patients affected by this disease. We believe that iscorEB has several advantages over BEBS and EBDASI. In this study, we have built upon our prior work that supported the content validity of iscorEB. We have demonstrated that iscorEB has good psychometric properties, such as reliability and construct validity, including a strong ability to differentiate between varying severities of EB. Based on this data, the instrument has been updated to include a different multiplier for skin scoring in children aged < 8 years, validated scoring for mouth opening and the addition of a different weight to inflammation and squamous cell carcinoma (File S1; see Supporting Information). Our next steps involve further testing of the modified instrument in a broader range of EB subtypes and measuring responsiveness in longitudinal cohorts and intervention trials (stem cell transplant).
